KALV vs KLRA

KalVista Pharmaceuticals, Inc. vs Kailera Therapeutics, Inc. — Valuation Comparison 2026

KALV

Biotechnology
KalVista Pharmaceuticals, Inc.
Quality
6.3
out of 10
Value Trap
38
LOW
Price
$26.77
Last close
Models
8/13
Active
VS

KLRA

Biotechnology
Kailera Therapeutics, Inc.
Quality
1.7
out of 10
Value Trap
Price
$22.94
Last close
Models
5/13
Active

Model-by-Model Comparison

ModelType KALV Fair ValueKALV Upside KLRA Fair ValueKLRA Upside
Bayesian DCF Intrinsic $8.49 -68.3% $6.77 -70.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $3.48 -84.8%
Dynamic NAV Asset-Based $5.03 -81.2%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for KALV vs KLRA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KALV vs KLRA — Which Stock Is More Undervalued?

KALV scores higher with a 6.3/10 quality rating vs KLRA's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing KalVista Pharmaceuticals, Inc. (KALV) and Kailera Therapeutics, Inc. (KLRA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KALV currently trades at $26.77 with a QOC of 6.3/10, while KLRA trades at $22.94 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).